Relacorilant is under clinical development by Corcept Therapeutics and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData, Phase II drugs for Bile Duct Cancer (Cholangiocarcinoma) have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Relacorilant’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Relacorilant (CORT-125134) is under development for the treatment of endogenous Cushing's syndrome, advanced/metastatic solid tumors such as platinum-resistant ovarian cancer, adrenocortical carcinoma, triple negative breast cancer, fallopian tube cancer, primary peritoneal cancer, metastatic castration-resistant prostate cancer. It is a small molecule administered orally. The drug candidate is a next-generation cortisol modulator that targets glucocorticoid receptor II (GR-II). It was also under development for metastatic pancreatic ductal adenocarcinoma..
Corcept Therapeutics overview
Corcept Therapeutics (Corcept) discovers, develops and commercializes innovative medicines for the treatment of psychiatric, oncologic and metabolic diseases. The company’s marketed product, Korlym (mifepristone), a cortisol receptor blocker, is indicated for the control of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome. Corcept’s major pipeline products include relacorilant for endogenous Cushing syndrome; miricorilant for NASH and antipsychotic-induced weight gain. It also has pipeline products in different phases of clinical trials indicated for the treatment of pancreatic cancer, ovarian cancer, adrenocortical cancer, amyotrophic lateral sclerosis, alcohol use disorder and post-traumatic stress disorder, among others. Corcept is headquartered in Menlo Park, California, the US.
For a complete picture of Relacorilant’s drug-specific PTSR and LoA scores, buy the report here.